GTC
BBOT

Ghost Tree Capital’s BridgeBio Oncology BBOT Stock Holding History

Ghost Tree Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.13M Hold
300,000
– – 0.95% 37
2024
Q2 		$3.07M Hold
300,000
– – 0.96% 38
2024
Q1 		$3.12M Buy
+300,000
New +$3.11M 0.86% 39

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Ghost Tree Capital's BBOT Position: Q3 2024 in Review

Ghost Tree Capital held its BridgeBio Oncology (BBOT) position steady in Q3 2024 at 300,000 shares worth $3.13M. The position accounts for 0.95% of the portfolio, ranked #37.

Ghost Tree Capital first reported a position in BBOT in Q1 2024 and has held it in 3 quarters since. 31 funds tracked by Wall St. Rank hold BBOT as of Q3 2024.

  • Ghost Tree Capital held 300,000 shares of BridgeBio Oncology worth $3.13M as of Q3 2024.
  • Ghost Tree Capital left its BridgeBio Oncology share count unchanged in Q3 2024.
  • BridgeBio Oncology made up 0.95% of Ghost Tree Capital's portfolio in Q3 2024, its #37 holding.
  • Ghost Tree Capital first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 3 quarters since.
  • 31 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.